Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin

Burkitt’s lymphoma (BL) is a highly aggressive malignancy molecularly characterized by deregulation of the C-MYC proto-oncogene. Recently, it has been confirmed that phosphatidylinositol-3-kinase (PI3K) pathway activation is a crucial element in the malignant transformation of the B cells in BL. Des...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Fan, Huang, Xianbo, Chen, Zhenzhen, Qian, Wenbin, Tong, Xiangmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820316/
https://www.ncbi.nlm.nih.gov/pubmed/29463831
http://dx.doi.org/10.1038/s41598-018-21570-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820316/
https://www.ncbi.nlm.nih.gov/pubmed/29463831
http://dx.doi.org/10.1038/s41598-018-21570-z

Ejemplares similares